Nephrol Dial Transplant (2002) 17: 2043-2047
© 2002 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes?
1 Department of Internal Medicine, Division of Cardiology, Ruperto Carola University, Heidelberg, Germany and 2 Division of Nephrology and Hypertension, University Hospital of Berne (Inselspital), Switzerland
Keywords: activator protein-1; intercellular adhesion molecule-1; interleukin-6; monocyte chemoattractant protein-1; nuclear factor-
B; tubular epithelial cells
| The first 150 words of the full text of this article appear below. |
MCP-1: a player in the pathogenesis of progression of renal diseases
There is an increasing body of evidence that the CC chemokine monocyte chemoattractant protein-1 (MCP-1) plays a major role in the pathogenesis of progression of renal failure. This is based on observations both in various animal models of renal damage and in different types of human renal disease (for review, see [1]). Locally produced MCP-1 seems to be particularly involved in the initiation and progression of tubulointerstitial damage. The latter has been documented in experiments using transgenic mice with nephrotic serum-induced nephritis: compared with wild-type mice, MCP-1-deficient mice exhibit less tubulointerstitial lesions, but they exhibit no differences in glomerular lesions [2]. There is, however, evidence that MCP-1 also plays a role in the progression of glomerular lesions, since glomerular expression of MCP-1 correlates with the degree of renal damage in inflammatory [3] and non-inflammatory [4] models of glomerular injury. Furthermore, in humans
MCP-1 induces an inflammatory activation of human tubular epithelial cells
Which receptor(s) is responsible for the mediation of effects of MCP-1 on human tubular epithelial cells?
Conclusion
Note added in proof
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Du, N. Hiramatsu, K. Hayakawa, A. Kasai, M. Okamura, T. Huang, J. Yao, M. Takeda, I. Araki, N. Sawada, et al. Suppression of NF-{kappa}B by Cyclosporin A and Tacrolimus (FK506) via Induction of the C/EBP Family: Implication for Unfolded Protein Response J. Immunol., June 1, 2009; 182(11): 7201 - 7211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cirillo, M. S. Gersch, W. Mu, P. M. Scherer, K. M. Kim, L. Gesualdo, G. N. Henderson, R. J. Johnson, and Y. Y. Sautin Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells J. Am. Soc. Nephrol., March 1, 2009; 20(3): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lui, S Yung, R Tsang, F Zhang, K. Chan, S Tam, and T. Chan Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice Lupus, April 1, 2008; 17(4): 305 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A. Vesey, W. A. Kruger, P. Poronnik, G. C. Gobe, and D. W. Johnson Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1441 - F1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-X. Wang and P. W. Sanders Immunoglobulin Light Chains Generate Hydrogen Peroxide J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1239 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Murali, A. W. Ackerman, A. J. Croatt, J. Cheng, J. P. Grande, S. L. Sutor, R. J. Bram, G. D. Bren, A. D. Badley, J. Alam, et al. Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease Am J Physiol Renal Physiol, February 1, 2007; 292(2): F837 - F844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Lehmann, S. Masanetz, S. Kramer, and V. Erfle HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner J. Cell Sci., November 1, 2006; 119(21): 4520 - 4530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Zager Parenteral Iron Compounds: Potent Oxidants but Mainstays of Anemia Management in Chronic Renal Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(Supplement_1): S24 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Zager, A. C. Johnson, S. Lund, S. Y. Hanson, and C. K. Abrass Levosimendan protects against experimental endotoxemic acute renal failure Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1453 - F1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hagiwara, Y. Makita, L. Gu, M. Tanimoto, M. Zhang, S. Nakamura, S. Kaneko, T. Itoh, T. Gohda, S. Horikoshi, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: Involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation Nephrol. Dial. Transplant., March 1, 2006; 21(3): 605 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lasaitiene, Y. Chen, G. Guron, N. Marcussen, A. Tarkowski, E. Telemo, and P. Friberg Perturbed medullary tubulogenesis in neonatal rat exposed to renin-angiotensin system inhibition Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2534 - 2541. [Abstract] [Full Text] [PDF]
|
|